International Stem Cell Corporation (ISCO)
USD 0.12
(20.0%)
USD 0.12
(20.0%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 4.6 Million USD | -7.84% |
| 2022 | 4.91 Million USD | 15.8% |
| 2021 | 4.24 Million USD | -2.44% |
| 2020 | 4.34 Million USD | -21.52% |
| 2019 | 5.53 Million USD | -21.1% |
| 2018 | 7.02 Million USD | 31.61% |
| 2017 | 5.33 Million USD | 2.16% |
| 2016 | 5.22 Million USD | -4.99% |
| 2015 | 5.49 Million USD | 7.83% |
| 2014 | 5.09 Million USD | 13.14% |
| 2013 | 4.5 Million USD | 36.69% |
| 2012 | 3.29 Million USD | 13.07% |
| 2011 | 2.91 Million USD | 245.33% |
| 2010 | 843.83 Thousand USD | 154.58% |
| 2009 | 331.45 Thousand USD | -11.26% |
| 2008 | 373.51 Thousand USD | 16827.0% |
| 2007 | -2233.00 USD | 92.02% |
| 2006 | -27.99 Thousand USD | 0.0% |
| 2005 | - USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 1.22 Million USD | 21.49% |
| 2024 Q2 | 1.39 Million USD | 16.13% |
| 2023 Q4 | 1 Million USD | -15.69% |
| 2023 Q1 | 1.26 Million USD | -2.47% |
| 2023 Q2 | 1.12 Million USD | -10.62% |
| 2023 FY | 4.52 Million USD | -7.84% |
| 2023 Q3 | 1.19 Million USD | 5.67% |
| 2022 Q2 | 1.3 Million USD | 1.08% |
| 2022 FY | 4.91 Million USD | 15.8% |
| 2022 Q4 | 1.29 Million USD | 27.74% |
| 2022 Q3 | 1.01 Million USD | -22.61% |
| 2022 Q1 | 1.29 Million USD | 16.88% |
| 2021 Q2 | 1.06 Million USD | 1.92% |
| 2021 Q3 | 1.02 Million USD | -3.29% |
| 2021 FY | 4.24 Million USD | -2.44% |
| 2021 Q1 | 1.04 Million USD | 25.21% |
| 2021 Q4 | 1.1 Million USD | 7.78% |
| 2020 Q2 | 1.09 Million USD | -27.28% |
| 2020 FY | 4.34 Million USD | -21.52% |
| 2020 Q3 | 918 Thousand USD | -16.01% |
| 2020 Q4 | 833 Thousand USD | -9.26% |
| 2020 Q1 | 1.5 Million USD | 7.28% |
| 2019 Q1 | 1.37 Million USD | -0.86% |
| 2019 Q4 | 1.4 Million USD | 8.02% |
| 2019 FY | 5.53 Million USD | -21.1% |
| 2019 Q2 | 1.46 Million USD | 6.32% |
| 2019 Q3 | 1.29 Million USD | -11.41% |
| 2018 Q2 | 1.94 Million USD | 7.47% |
| 2018 Q4 | 1.38 Million USD | -26.12% |
| 2018 FY | 7.02 Million USD | 31.61% |
| 2018 Q1 | 1.8 Million USD | 48.44% |
| 2018 Q3 | 1.88 Million USD | -3.24% |
| 2017 Q3 | 1.37 Million USD | 6.35% |
| 2017 FY | 5.33 Million USD | 2.16% |
| 2017 Q1 | 1.45 Million USD | 17.57% |
| 2017 Q4 | 1.21 Million USD | -11.29% |
| 2017 Q2 | 1.29 Million USD | -11.09% |
| 2016 FY | 5.22 Million USD | -4.99% |
| 2016 Q4 | 1.23 Million USD | -7.63% |
| 2016 Q3 | 1.33 Million USD | -5.18% |
| 2016 Q2 | 1.41 Million USD | 13.8% |
| 2016 Q1 | 1.23 Million USD | -12.81% |
| 2015 Q3 | 1.57 Million USD | 20.94% |
| 2015 Q2 | 1.29 Million USD | 7.89% |
| 2015 FY | 5.49 Million USD | 7.83% |
| 2015 Q1 | 1.2 Million USD | -4.6% |
| 2015 Q4 | 1.42 Million USD | -9.55% |
| 2014 FY | 5.09 Million USD | 13.14% |
| 2014 Q4 | 1.26 Million USD | -12.66% |
| 2014 Q1 | 1.21 Million USD | 0.67% |
| 2014 Q2 | 1.17 Million USD | -2.56% |
| 2014 Q3 | 1.44 Million USD | 22.56% |
| 2013 Q4 | 1.2 Million USD | -1.72% |
| 2013 FY | 4.5 Million USD | 36.69% |
| 2013 Q1 | 951 Thousand USD | 2.04% |
| 2013 Q2 | 1.12 Million USD | 18.61% |
| 2013 Q3 | 1.22 Million USD | 8.42% |
| 2012 Q4 | 932 Thousand USD | 7.5% |
| 2012 FY | 3.29 Million USD | 13.07% |
| 2012 Q1 | 753 Thousand USD | 26.65% |
| 2012 Q2 | 743 Thousand USD | -1.33% |
| 2012 Q3 | 867 Thousand USD | 16.69% |
| 2011 Q3 | 481.34 Thousand USD | -36.01% |
| 2011 Q2 | 752.17 Thousand USD | -30.73% |
| 2011 FY | 2.91 Million USD | 245.33% |
| 2011 Q1 | 1.08 Million USD | 272.67% |
| 2011 Q4 | 594.55 Thousand USD | 23.52% |
| 2010 Q2 | 226.78 Thousand USD | 79.63% |
| 2010 Q1 | 126.25 Thousand USD | -37.65% |
| 2010 FY | 843.83 Thousand USD | 154.58% |
| 2010 Q3 | 199.41 Thousand USD | -12.07% |
| 2010 Q4 | 291.39 Thousand USD | 46.13% |
| 2009 Q1 | -106.86 Thousand USD | -216.68% |
| 2009 Q4 | 202.49 Thousand USD | 88.9% |
| 2009 Q3 | 107.19 Thousand USD | -16.66% |
| 2009 Q2 | 128.63 Thousand USD | 220.37% |
| 2009 FY | 331.45 Thousand USD | -11.26% |
| 2008 Q4 | 91.58 Thousand USD | -55.14% |
| 2008 Q2 | 66.29 Thousand USD | 477.85% |
| 2008 Q1 | 11.47 Thousand USD | -65.89% |
| 2008 FY | 373.51 Thousand USD | 16827.0% |
| 2008 Q3 | 204.15 Thousand USD | 207.94% |
| 2007 FY | -2233.00 USD | 92.02% |
| 2007 Q4 | 33.63 Thousand USD | 195.56% |
| 2007 Q1 | -2699.00 USD | 86.86% |
| 2007 Q2 | 2026.00 USD | 175.06% |
| 2007 Q3 | -35.19 Thousand USD | -1837.17% |
| 2006 Q2 | -14.17 Thousand USD | -1728.39% |
| 2006 FY | -27.99 Thousand USD | 0.0% |
| 2006 Q1 | -775.00 USD | 0.0% |
| 2006 Q4 | -20.54 Thousand USD | 0.0% |
| 2006 Q3 | - USD | 100.0% |
| 2005 FY | - USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Arch Therapeutics, Inc. | -2439.00 USD | 189029.889% |
| Evofem Biosciences, Inc. | 11.7 Million USD | 60.636% |
| Nascent Biotech, Inc. | -319.5 Thousand USD | 1542.222% |
| Rebus Holdings, Inc. | - USD | -Infinity% |
| Santhera Pharmaceuticals Holding AG | 119.1 Million USD | 96.131% |
| Qrons Inc. | - USD | -Infinity% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | -25.79 Million USD | 117.862% |
| ProtoKinetix, Incorporated | -48.25 Thousand USD | 9648.478% |
| Skye Bioscience, Inc. | -124.25 Thousand USD | 3808.622% |
| Eiger BioPharmaceuticals, Inc. | 14.99 Million USD | 69.278% |
| Nanobac Pharmaceuticals, Incorporated | 3102.00 USD | -148449.323% |
| Institute of Biomedical Research Corp. | - USD | -Infinity% |
| SQZ Biotechnologies Company | 9.79 Million USD | 52.951% |
| Intellipharmaceutics International Inc. | 65.72 Thousand USD | -6910.711% |
| Propanc Biopharma, Inc. | -34.15 Thousand USD | 13593.411% |
| Mesoblast Limited | -35.16 Million USD | 113.103% |
| Marizyme, Inc. | 457.7 Thousand USD | -906.769% |
| Genus plc | 178.7 Million USD | 97.421% |
| VioQuest Pharmaceuticals, Inc. | - USD | -Infinity% |
| Pharming Group N.V. | 220.1 Million USD | 97.906% |
| Therapeutic Solutions International, Inc. | 62.22 Thousand USD | -7305.265% |
| CNBX Pharmaceuticals Inc. | 410.16 Thousand USD | -1023.45% |
| Nymox Pharmaceutical Corporation | -11 Thousand USD | 41990.909% |
| ContraFect Corporation | -154 Thousand USD | 3092.208% |
| PsyBio Therapeutics Corp. | -50 Thousand USD | 9316.0% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 76.76 Thousand USD | -5903.048% |
| IMV Inc. | -962.29 Thousand USD | 578.854% |
| AXIM Biotechnologies, Inc. | -387.5 Thousand USD | 1289.158% |
| MultiCell Technologies, Inc. | 49.32 USD | -9342965.693% |
| ONE Bio Corp. | 20.12 Million USD | 77.104% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 40.26 Million USD | 88.556% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 48.9 Thousand USD | -9323.313% |
| Q BioMed Inc. | -8988.00 USD | 51368.358% |
| Emmaus Life Sciences, Inc. | 28.25 Million USD | 83.691% |
| Mosaic ImmunoEngineering Inc. | - USD | -Infinity% |
| Biomind Labs Inc. | -15.42 Thousand USD | 29975.519% |
| American Oriental Bioengineering, Inc. | 44.35 Million USD | 89.612% |
| Provectus Biopharmaceuticals, Inc. | -1.14 Million USD | 503.654% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 70 Thousand USD | -6482.857% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | -4952.00 USD | 93153.312% |
| Acro Biomedical Co., Ltd. | 140.5 Thousand USD | -3179.715% |
| Curative Biotechnology, Inc. | -97.51 Thousand USD | 4825.427% |
| GB Sciences, Inc. | -624.00 USD | 738561.538% |
| Alpha Cognition Inc. | -86.02 Thousand USD | 5456.396% |
| HST Global, Inc. | - USD | -Infinity% |
| CSL Limited | 7.56 Billion USD | 99.939% |
| Wesana Health Holdings Inc. | - USD | -Infinity% |
| Halberd Corporation | -208.00 USD | 2215484.615% |
| Enzolytics Inc. | 30.7 Thousand USD | -14905.862% |
| Agentix Corp. | - USD | -Infinity% |
| Resverlogix Corp. | - USD | -Infinity% |
| Nuo Therapeutics, Inc. | 482.43 Thousand USD | -855.159% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.1 Billion USD | 99.584% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Endonovo Therapeutics, Inc. | -514.51 Thousand USD | 995.609% |
| RespireRx Pharmaceuticals Inc. | - USD | -Infinity% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | 617.38 Thousand USD | -646.375% |
| Zenith Capital Corp. | - USD | -Infinity% |
| Genscript Biotech Corporation | 409.55 Million USD | 98.875% |
| Ember Therapeutics, Inc. | - USD | -Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | -8856.00 USD | 52132.52% |
| WPD Pharmaceuticals Inc. | - USD | -Infinity% |
| Cotinga Pharmaceuticals Inc. | -83.84 Thousand USD | 5595.593% |
| Kadimastem Ltd | -630.13 Thousand USD | 831.268% |
| Helix BioMedix, Inc. | 987.98 Thousand USD | -366.406% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 9.61 Million USD | 52.055% |
| BioStem Technologies, Inc. | 15.42 Million USD | 70.126% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | - USD | -Infinity% |
| LadRx Corporation | -11.83 Thousand USD | 39035.361% |
| Cell Source, Inc. | - USD | -Infinity% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | -2509.878% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | -2509.878% |
| NovAccess Global Inc. | - USD | -Infinity% |
| Affymax, Inc. | 1.35 Million USD | -239.537% |
| Itoco Inc. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | - USD | -Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | - USD | -Infinity% |
| CytoDyn Inc. | -29 Thousand USD | 15989.655% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Alseres Pharmaceuticals, Inc. | 450.04 Thousand USD | -923.902% |
| SYBLEU INC | 11.69 Thousand USD | -39298.085% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | - USD | -Infinity% |
| Bioxytran, Inc. | -8285.00 USD | 55718.588% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | - USD | -Infinity% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | - USD | -Infinity% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | - USD | -Infinity% |
| Innovation Pharmaceuticals Inc. | -373 Thousand USD | 1335.389% |
| Neutra Corp. | 14.33 Thousand USD | -32045.099% |
| Windtree Therapeutics, Inc. | -82 Thousand USD | 5719.512% |
| PureTech Health plc | -1.6 Million USD | 387.461% |
| Coeptis Therapeutics, Inc. | -1 Million USD | 560.231% |
| IXICO plc | 3.27 Million USD | -40.917% |
| IntelGenx Technologies Corp. | -694 Thousand USD | 763.977% |
| Gelesis Holdings, Inc. | -1.79 Million USD | 357.286% |
| CSL Limited | 7.7 Billion USD | 99.94% |
| Cellectis S.A. | 18 Thousand USD | -25500.0% |